ERBB2 and neoplasm: Indeed, it has been reported that the administration of anti-PD1 monoclonal antibody (mAb) in immunocompetent mice could enhance the therapeutic activity of anti-HER2 mAb by enhancing the adaptive anti-tumor immune response [33].